BioCentury | Nov 8, 2019
Clinical News

Roche’s RG6206 becomes second myostatin inhibitor to fail in DMD in past year

...In August 2018, Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of anti-MSTN mAb domagrozumab (PF-06252616...
BioCentury | Apr 12, 2019
Clinical News

Acceleron discontinues ACE-2494 due to antidrug antibodies

...developing an MSTN-targeted therapy. In August, the pharma terminated two Phase II trials of domagrozumab (PF-06252616...
BioCentury | Sep 7, 2018
Company News

Pfizer, Cytoo to develop DMD muscle-on-a-plate platform

...not disclosed. In August, the pharma discontinued two Phase II trials of DMD candidate domagrozumab (PF-06252616...
BioCentury | Aug 31, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy...
...Impair Muscular Atrophy and Dystrophy Treatments” ). Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Domagrozumab (PF-06252616...
...4 Stair Climb (4SC) test; B5161004: Safety Status: Phase II discontinued Milestone: NA Jaime De Leon domagrozumab (PF-06252616) PF-06939926 Pfizer...
BioCentury | Aug 30, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...Pfizer Inc. (NYSE:PFE) terminated two Phase II trials of domagrozumab (PF-06252616) to treat Duchenne muscular dystrophy...
...DMD (see “Low Levels of Myostatin Impair Muscular Atrophy and Dystrophy Treatments” ). Jaime De Leon domagrozumab (PF-06252616) PF-06939926 Pfizer...
BioCentury | Nov 9, 2015
Strategy

Pfizer's growth spurt

...was not powered to detect statistical significance. Pfizer's most advanced homegrown rare disease candidates are PF-06252616...
...they could be candidates for accelerated approval. In a Phase I trial in healthy volunteers, PF-06252616...
BioCentury | Mar 2, 2015
Product Development

The roots of rarity

...amyloid polyneuropathy (TTR-FAP); cardiomyopathy Registration (TTR-FAP); Ph III (cardiomyopathy) FoldRx Pharmaceuticals Inc. (acquired 2010) Anti-GDF8 (PF-06252616...
BioCentury | Jan 5, 2015
Clinical News

PF-06252616: Phase II started

...a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 5, 20 and 40 mg/kg IV PF-06252616...
...Fast Track designation in the U.S. for DMD. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: PF-06252616...
Items per page:
1 - 8 of 8